[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620342":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":28,"locations":10,"responsibleParty":34,"collaborators":10,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":10,"enrollmentInfo":47,"targetDuration":10,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":10},{"fullName":5,"class":6},"University of Sao Paulo General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Iloprost to Selexipag Transition",null,"Adult patients with pulmonary arterial hypertension receiving inhaled iloprost whose treating physician decides, as part of routine clinical care, to transition treatment to oral selexipag. Patients are followed prospectively to assess changes in patient-reported outcomes, treatment satisfaction, and adherence before and after the transition. All treatment decisions are made by the treating physician, and no study-related intervention is performed.",[13],"Drug: Selexipag",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Selexipag","Exposure to oral selexipag following transition from inhaled iloprost as part of routine clinical care in adults with pulmonary arterial hypertension. The decision to initiate, titrate, or discontinue selexipag is made exclusively by the treating physician, independent of study participation. No study-mandated intervention or treatment assignment is performed. The study observes patient-reported outcomes, treatment satisfaction, and adherence associated with this treatment transition.",[9],[21,22],"Oral selexipag","IP receptor agonist",[24],{"name":25,"affiliation":26,"role":27},"Caio Fernandes, MD","UNIVERSIDADE SAO PAULO","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Caio Fernandes Principal Investigator, MD","CONTACT","+551126615034","cjcfernandes@yahoo.com.br",{"type":27,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Caio Júlio César dos Santos Fernandes","Pulmonologist, PhD","100620342","patient-reported-outcomes-and-adherence-after-transition-from-inhaled-iloprost-to-oral-selexipag-in-pulmonary-arterial-hypertension-100620342",false,"NCT07356375","Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension","PROMISE: Evaluation of Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension","PROMISE","Inclusion Criteria\n\n* Adults aged 18 years or older.\n* Confirmed diagnosis of pulmonary arterial hypertension (PAH, Group 1) by right heart catheterization.\n* Current treatment with inhaled iloprost as part of routine clinical care.\n* Clinical decision by the treating physician to transition from inhaled iloprost to oral selexipag.\n* Ability to understand and complete patient-reported outcome questionnaires.\n* Provision of written informed consent.\n\nExclusion Criteria\n\n* Significant cognitive impairment or sensory deficits that prevent completion of study questionnaires.\n* Unstable or decompensated comorbid conditions that may interfere with treatment adherence or study participation.\n* Refusal or inability to provide informed consent.","ALL","18 Years",{"count":48,"type":49},32,"ESTIMATED","OBSERVATIONAL","Pulmonary arterial hypertension (PAH) is a rare and serious condition that affects the blood vessels of the lungs and can significantly limit daily activities and quality of life. Some patients with PAH use inhaled iloprost, a medication that requires several inhalations per day, which can be difficult to maintain over time. Oral selexipag is an alternative treatment that may reduce treatment burden and improve adherence.\n\nThe PROMISE study aims to evaluate how switching from inhaled iloprost to oral selexipag affects patients' quality of life, satisfaction with treatment, and adherence in real-world clinical practice. Patient-reported outcome questionnaires will be used to understand patients' perceptions of symptoms, daily functioning, and overall improvement after the transition.\n\nAdult patients with PAH who are receiving inhaled iloprost and whose physicians decide to switch treatment to oral selexipag will be followed over time. A comparison group of patients who continue using inhaled iloprost will also be observed. The study does not involve any experimental treatment or changes to routine clinical care. All medications are prescribed as part of standard medical practice.\n\nThe results of this study may help improve understanding of the patient experience during treatment transitions in PAH and support more patient-centered treatment decisions.",[53],"Pulmonary Arterial Hypertension (PAH)",[55,56,57,58,59,60,61,17,62],"Pulmonary Arterial Hypertension","Prostacyclin Pathway","Patient-Reported Outcomes","Quality of Life","Treatment Adherence","Real-World Evidence","Iloprost","Observational Study","NOT_YET_RECRUITING","2026-02-10",{"date":66,"type":67},"2026-02-13","ACTUAL",{"date":69,"type":49},"2026-03-01",{"date":71,"type":49},"2026-12-31",{"name":5,"class":6}]